The estimated Net Worth of Jean Frederic Viret is at least $3.53 million dollars as of 1 February 2021. Jean Viret owns over 7,402 units of Coherus Biosciences Inc stock worth over $91,367 and over the last 10 years he sold CHRS stock worth over $1,605,859. In addition, he makes $1,829,590 as Chief Financial Officer at Coherus Biosciences Inc.
Jean has made over 27 trades of the Coherus Biosciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 7,402 units of CHRS stock worth $74,390 on 1 February 2021.
The largest trade he's ever made was selling 46,144 units of Coherus Biosciences Inc stock on 25 January 2021 worth over $920,573. On average, Jean trades about 3,519 units every 44 days since 2014. As of 1 February 2021 he still owns at least 68,697 units of Coherus Biosciences Inc stock.
You can see the complete history of Jean Viret stock trades at the bottom of the page.
Dr. Jean-Frederic Viret Ph.D. serves as Chief Financial Officer of the Company. He has served as the Company’s Chief Financial Officer since September 2014. Previously, Dr. Viret was Chief Financial Officer at diaDexus, Inc., a cardiovascular diagnostics company, from February 2012 to September 2014. diaDexus, Inc. filed a voluntary petition for bankruptcy in June 2016. Prior to that, Dr. Viret was Chief Financial Officer at XDx, Inc. (now CareDx, Inc.), a privately held molecular diagnostics company, from December 2009 to January 2012. From March 2009 to December 2009, Dr. Viret served as the President of JV Consulting, a private consulting firm that provided accounting, public company compliance and other financial consulting services to technology companies. Prior to that time, Dr. Viret served in various capacities at Anesiva, Inc. (previously known as Corgentech Inc.), a public biopharmaceutical company, most recently as a finance consultant from February 2009 to May 2009. Dr. Viret served as Anesiva’s Vice President and Chief Financial Officer from March 2008 to February 2009 and as its Vice President, Finance from August 2006 to February 2008. Dr. Viret held various positions in finance in Anesiva from December 2002 to August 2006 and at Tularik Inc. from March 2000 to November 2002. He held various positions in the business assurance services of PricewaterhouseCoopers LLP from September 1997 to March 2000. Dr. Viret has also served on the Board of Directors of RubrYc Therapeutics, Inc. since October 2018. Dr. Viret received a B.S. in Engineering from the Institut National Polytechnique de Lorraine, an M.B.A. from Cornell University and a Ph.D. in Plant Molecular Biology from Université Louis Pasteur (Strasbourg I). He was a visiting fellow at Harvard University and a postdoctoral fellow at the Massachusetts Institute of Technology.
As the Chief Financial Officer of Coherus Biosciences Inc, the total compensation of Jean Viret at Coherus Biosciences Inc is $1,829,590. There are 1 executives at Coherus Biosciences Inc getting paid more, with Dennis Lanfear having the highest compensation of $5,361,710.
Jean Viret is 54, he's been the Chief Financial Officer of Coherus Biosciences Inc since 2014. There are 12 older and 3 younger executives at Coherus Biosciences Inc. The oldest executive at Coherus Biosciences Inc is Dr. Barbara K. Finck M.D., 74, who is the Acting Chief Medical Officer.
Jean's mailing address filed with the SEC is C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Coherus Biosciences Inc have traded over $94,360,509 worth of Coherus Biosciences Inc stock and bought 594,589 units worth $8,026,656 . The most active insiders traders include Llc Fmr, August J. Troendle et James Healy. On average, Coherus Biosciences Inc executives and independent directors trade stock every 26 days with the average trade being worth of $64,928. The most recent stock trade was executed by Mats Wahlstrom on 1 February 2024, trading 59,988 units of CHRS stock currently worth $100,180.
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
Coherus Biosciences Inc executives and other stock owners filed with the SEC include: